Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Year: 2021
Type: article
Authors: Rajeshwari Sridhara, Olga Marchenko, Qi Jiang, Richard Pazdur, Martin Posch, Mary Redman, Yevgen Tymofyeyev, Xiaoyun (Nicole) Li, Marc Theoret, Yuan Li Shen, Thomas Gwise, Lorenzo Hess, Michael Coory, Andrew Raven, Naoto Kotani, Kit Roes, Filip Josephson, Scott Berry, Richard Simon, Bruce Binkowitz
Institutions: United States Food and Drug Administration, Bayer (United States), Seagen (United States), Medical University of Vienna, Fred Hutch Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Swissmedic, Government of Western Australia Department of Health, Pharmaceuticals and Medical Devices Agency, Medical Products Agency, Berry Consultants, LLC (United States), Shionogi (United States)
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: closed
Funder: Children's Tumor Foundation
OpenAlex ID: W3136509527